A pharmacokinetic study to compare two simultaneous 400 μg doses with a single 800 μg dose of oral transmucosal fentanyl citrate

被引:15
作者
Lee, M
Kern, SE
Kisicki, JC
Egan, TD
机构
[1] Univ Utah, Dept Pharmaceut, Salt Lake City, UT 84108 USA
[2] Univ Utah, Coll Pharm, Salt Lake City, UT 84112 USA
[3] Univ Utah, Dept Anesthesiol, Salt Lake City, UT 84112 USA
[4] MDS Harris Labs, Lincoln, NE USA
关键词
fentanyl; Actiq; OTFC; pharmacokinetics; bioequivalence; opioids;
D O I
10.1016/S0885-3924(03)00241-0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
It is unknown whether two smaller doses of oral transmucosal fentanyl citrate (OTFC) administered simultaneously are pharmacokinetically equivalent to an identical dose administered as a single unit. This issue has important practical implications when patients are attempting to identify the appropriate dosage of OTFC to control their pain. This open-label, randomized, crossover design study compared the pharmacokinetics of two simultaneously consumed 400 mug OTFC doses with one 800 mug OTFC dose in 12 healthy volunteers. The two treatments were pharmacokinetically equivalent. The maximum concentration produced for each dosage group (Cmax) was 1.09 ng/ml for two 400 mug dose and 1.10 ng/ml for one 800 jug dose. Area under the curve (AUC) was 8.2 ng/ml.hr (SE = 1.1) and 7.2 ng/ml-hr (SE = 1.0). There were no significant differences between the treatment groups in either the time to peak concentration (Tmax) or the mean residence time (MRT). The results demonstrate the bioequivalence of two 400 mug with one 800 mug OTFC units. (C) 2003 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:743 / 747
页数:5
相关论文
共 8 条
[1]   A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone [J].
Benziger, DP ;
Miotto, J ;
Grandy, RP ;
Thomas, GB ;
Swanton, RE ;
Fitzmartin, RD .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 13 (02) :75-82
[2]  
CEPHALON I, 2002, ACTIQ PACKAGE INSERT
[3]   Breakthrough cancer pain:: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®) [J].
Coluzzi, PH ;
Schwartzberg, L ;
Conroy, JD ;
Charapata, S ;
Gay, M ;
Busch, MA ;
Chavez, J ;
Ashley, J ;
Lebo, D ;
McCracken, M ;
Portenoy, RK .
PAIN, 2001, 91 (1-2) :123-130
[4]  
KAIKO RF, 1989, CANCER, V63, P2348, DOI 10.1002/1097-0142(19890601)63:11<2348::AID-CNCR2820631146>3.0.CO
[5]  
2-V
[6]   Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study [J].
Portenoy, RK ;
Payne, R ;
Coluzzi, P ;
Raschko, JW ;
Lyss, A ;
Busch, MA ;
Frigerio, V ;
Ingham, J ;
Loseth, DB ;
Nordbrock, E ;
Rhiner, M .
PAIN, 1999, 79 (2-3) :303-312
[7]   Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate [J].
Streisand, JB ;
Busch, MA ;
Egan, TD ;
Smith, BG ;
Gay, M ;
Pace, NL .
ANESTHESIOLOGY, 1998, 88 (02) :305-309
[8]   ABSORPTION AND BIOAVAILABILITY OF ORAL TRANSMUCOSAL FENTANYL CITRATE [J].
STREISAND, JB ;
VARVEL, JR ;
STANSKI, DR ;
LEMAIRE, L ;
ASHBURN, MA ;
HAGUE, BI ;
TARVER, SD ;
STANLEY, TH .
ANESTHESIOLOGY, 1991, 75 (02) :223-229